Context Therapeutics Management
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Martin Lehr (38 yo)
Mr. Martin A. Lehr serves as Independent Director of Praesidia Biotherapeutics, Inc. He is the Co-founder, President, Chief Executive Officer and Director of Context Therapeutics Inc., since 2015. He was a...
CEO Compensation Analysis
|Martin Lehr's Compensation vs Context Therapeutics Earnings|
|Date||Total Comp.||Salary||Company Earnings|
|Jun 30 2022||n/a||n/a|
|Mar 31 2022||n/a||n/a|
|Dec 31 2021||US$2m||US$291k|
|Sep 30 2021||n/a||n/a|
|Jun 30 2021||n/a||n/a|
|Mar 31 2021||n/a||n/a|
|Dec 31 2020||US$250k||US$250k|
|Dec 31 2019||US$250k||US$250k|
Compensation vs Market: Martin's total compensation ($USD1.59M) is above average for companies of similar size in the US market ($USD772.00K).
Compensation vs Earnings: Martin's compensation has increased whilst the company is unprofitable.
Experienced Management: CNTX's management team is not considered experienced ( 1.1 years average tenure), which suggests a new team.
Experienced Board: CNTX's board of directors are not considered experienced ( 1.5 years average tenure), which suggests a new board.